Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEAR-NK
- Development stage
- Preclinical
- Lead developer
- Coeptis Pharmaceuticals
- Modality
- Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GEAR-NK is a gene-edited, autologous natural killer (NK) cell therapy platform designed to enhance the efficacy of combination cancer treatments, particularly for blood cancers. By editing NK cells to be resistant to monoclonal antibody (mAb) therapies, GEAR-NK allows these immune cells to be co-administered with targeted mAbs (such as anti-CD38), overcoming the problem of NK cell fratricide and neutralization caused by shared antigen expression with malignant cells. The platform aims to optimize immune cell function and is in preclinical development for hematologic malignancies and potentially other cancers. GEAR-NK was developed through a partnership between COEPTIS, Inc. (and its majority-owned subsidiary GEAR Therapeutics) and originating technology from VyGen-Bio, with academic research roots at the Karolinska Institutet. The first-in-human studies are planned to target multiple myeloma and other cancers, with future potential for use in combination with hematopoietic stem cell therapies to improve bone marrow transplant outcomes[1][3][5][7][9].
- Brand names
- GEAR-NK
- Other names
- Gene-Edited Antibody Resistant NK cellsGEAR-modified natural killer cells
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on GEAR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEAR-NK.